Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952001 · ClinicalTrials.gov registry record
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
A clinical trial of Uveitis and Uveitis, Posterior, sponsored by Clearside Biomedical.
- Completed
- Registry status
- 33
- Enrollment target
- 16
- Study locations
NCT02952001 is a study of Uveitis and Uveitis, Posterior that has completed, run by Clearside Biomedical. The registered enrollment target is 33 participants, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT02952001, a study of Uveitis and Uveitis, Posterior, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.
Conditions Studied
Interventions
- DRUG Sham procedure
- DRUG 4 mg CLS-TA Suprachoriodal Injection
Study Locations (16)
Texas
- Texas Retina Associates - Dallas
- Retina Consultants of Houston - The Woodlands
Other
- Disha Eye Hospitals Pvt. Ltd. - Kolkata
- Dr Rajendra Prasad Centre for Ophthalmic Sciences - New Delhi
Arizona
- Retinal Consultants of Arizona - Phoenix
California
- Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
Florida
- Retina Group of Florida - Fort Lauderdale
Georgia
- Marietta Eye Clinic - Marietta
Massachusetts
- Valley Eye Physicians and Surgeons, PC - Ayer
North Dakota
- Bergstrom Eye Research - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2018-05-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02952001
The ClinicalTrials.gov registry entry for NCT02952001 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 616-participant average among 19 other Uveitis trials with a reported enrollment target (95% lower). The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Sham procedure is the first listed.
NCT02952001 reports 16 study locations spanning 14 distinct geographic areas - top geographies include Texas, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT02952001 about?
NCT02952001 is a clinical study titled "MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301". This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspens...
What is the current status of trial NCT02952001?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2017-12-13. Estimated completion is 2018-05-22.
What conditions does trial NCT02952001 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate, Uveitis, Anterior, Panuveitis.
What interventions are being tested in trial NCT02952001?
The interventions under investigation include: Sham procedure (DRUG), 4 mg CLS-TA Suprachoriodal Injection (DRUG).
Who is sponsoring clinical trial NCT02952001?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02952001 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.